



## ***BROAD STREET ALERTS***

**New Growth Report: BioStem Technologies, Inc. (OTC: BSEM) 06/27/2024**

### **BSEM Key Highlights**

**Completed an extensive two-year audit in preparation for moving BSEM to a national exchange. (NASDAQ or NYSE)**

**Recently released their Q1 earnings, which shocked the market with revenues totaling \$41 million in the first quarter of 2024.**

**First positive net income of over \$4.4 million in the quarter.**

**Analyst Target \$23.75 representing a 153% upside from the current price of \$9.38**

**Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach \$18.4 billion by 2028.**



## **BIOSTEM TECHNOLOGIES INC. (OTC: BSEM)**

### **AN EMERGING COMPANY IN THE MEDTECH SPACE WITH A \$23.25 ZACKS PRICE TARGET AND INCREASING REVENUES**

**The MedTech sector, often overlooked, is just as innovative as many top tech names. BioStem Technologies Inc. (OTC: BSEM) positions itself as a top medtech stock to watch, with massive multi-billion-dollar markets for its regenerative therapies.**

**The company recently released its Q1 earnings, which shocked the market with revenues totaling \$41 million in the first quarter of 2024. The last six months have been pivotal for BSEM as it continues to reach new milestones.**

**Navigating the medtech arena is challenging due to the diverse types of companies within it. Emerging players like BSEM, who successfully navigate the regulatory process—a significant barrier to entry—and show real growth, are crucial. Zack's Small Cap Research recently increased its price target to \$23.25, recognizing the company's value after its Q1 financial results. This is the third time in the past few months that Zack's has raised its price target for BSEM, seeing significant value in the company.**

#### **Key Highlights from Q1 Earnings:**

**Revenues of \$41.9 million represented nearly a 71-fold increase over the year-ago period.**

**Margins improved to 95%, with management noting that this rate should continue.**

**The US Patent Office prioritized examining the patent for BioREtain processing technology.**

**The company has retained an experienced clinical research professional to lead trials for diabetic foot ulcers and venous leg ulcers.**

**First positive net income of over \$4.4 million in a quarter.**

**Completed an extensive two-year audit in preparation for moving BSEM to a national exchange.**

#### **Operational and Financial Progress in 2023:**

**A year-over-year net revenue increase of 1,355% to \$11.5 million in Q4, with a gross profit margin reaching 95%.**

**Expanded capabilities by acquiring assets from Auxocell Laboratories, launching AmnioWrap2 nationwide, and initiating a clinical trial for diabetic foot ulcers.**

**Secured commercialization agreements for Avenova Allograft™ and achieved CMS reimbursement for Vendaje AC® and AmnioWrap2.**

**Strengthened leadership by appointing two new board members.**

#### **Recent Milestones:**

**Preliminary net revenue for Q4 2023 was \$11.5 million, a 1,351% increase from the same period in 2022.**

**Total preliminary net revenue for fiscal year 2023 was \$16.7 million, a 142% increase compared to the previous year.**

**Announced a Healthcare Common Procedure Coding System code for Vendaje AC, effective January 2024.**

**Closed an oversubscribed private placement for gross proceeds of \$2 million.**

**Opened the first site for a clinical trial evaluating Vendaje® tissue allograft for diabetic foot ulcers.**

**Entered an agreement with Venture Medical, LLC., for the nationwide release of AmnioWrap2™.**

**Entered a commercialization agreement with NovaBay Pharmaceuticals for the Avenova Allograft.**

**About BioStem Technologies:**

**BioStem Technologies is focused on harnessing the natural properties of perinatal tissue for developing, manufacturing, and commercializing allografts for regenerative therapies. The company's mission is to discover, develop, and produce the most effective regenerative medicine products in the world. They manufacture perinatal tissue allografts, focusing on the diabetic wound care and surgical wound care markets.**

## **Regenerative Medicine:**

**Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach \$18.4 billion by 2028.**

## **Harnessing Placental Tissue:**

**BSEM manufactures tissue allografts derived from the human placenta, processed using the proprietary BioRetain® method. The company's portfolio includes VENDAJE™, VENDAJE™ AC, VENDAJE™ OPTIC, and AMNIOWRAP2, processed at its FDA-registered and AATB-accredited site in Pompano Beach, Florida.**

## **Two Big Markets:**

**BSEM's products target the growing diabetes wound care and surgical recovery wound care markets. The global wound care market is expected to grow to \$27.2 billion by 2027, with the US advanced wound care market reaching \$17.7 billion. The global diabetic foot ulcer treatment market is projected to expand significantly, providing promising potential for BSEM's impact on patients and business expansion.**

## **Reasons to Watch BSEM:**

**Working with notable clients and partners, including CMS and the VA.**

**Experienced sales and marketing leadership team.**

**Acquisition of assets from Auxocell Laboratories to expand its intellectual property portfolio.**

Produced over 20,000 allografts, including the Vendaje® line.

Quality management system accredited by AATB and FDA.

### Daily Chart

Published on TradingView.com, Jun 26, 2024 21:19 UTC-4



TradingView

**Current Price: \$9.38**

**Analyst Target: \$23.75**

## Share Structure

### BSEM SECURITY DETAILS

---

#### Share Structure

---

Market Cap <sup>Q1</sup>	143,491,483	06/25/2024
Authorized Shares	975,000,000 <sup>U</sup>	06/24/2024
Outstanding Shares	16,287,342 <sup>U</sup>	06/24/2024
Restricted	7,399,233 <sup>U</sup>	06/24/2024
Unrestricted	8,888,109 <sup>U</sup>	06/24/2024
Held at DTC	6,868,672 <sup>U</sup>	06/24/2024
Float	6,230,225	12/19/2023
Par Value	0.001	

## Conclusion:

**BioStem Technologies (BSEM) is making significant strides in regenerative medicine, particularly in wound care. With surging revenues, strategic partnerships, and regulatory milestones, BSEM is poised for continued growth. Keep an eye on this emerging MedTech company as it advances its mission to provide innovative wound care solutions and generate value for shareholders.**

The Team

## Privacy Policy and Disclaimer

### Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

### Do we disclose any information to outside parties?

We do not sell your information to anyone.

### What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

### What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.

We send periodic emails.

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

### How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

## Online Privacy Policy



This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Editor@TradersNewsSource.com

(NOTE Small Cap Specialists LLC is Now Media Source LLC)

Disclaimer

BroadStreetAlerts.com is a wholly owned subsidiary of Media Source LLC, herein referred to as SCS LLC.

This website / media webpage is owned, operated, and edited by Media Source LLC. Any wording found on this website / media webpage or disclaimer referencing to "I" or "we" or "our" or "SCS LLC" refers to Media Source LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. SCS LLC's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator's, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is

incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.

All information on featured companies is provided by the companies profiled or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

SCS LLC is compliant with the Can-Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. We have been compensated twelve thousand five hundred dollars cash via bank wire by Sideways Frequency LLC for investor relations and marketing services of BSEM starting 06/27/2024 and lasting one day through 06/27/2024. We do not hold any form of equity in BSEM.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.

SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.